Stephen Charles


As an Executive-in-Residence with BioEnterprise, Stephen provides executive consulting to pharmaceutical, biologics, and diagnostics companies. Currently he is the CEO for Lobesity, an early stage company with a novel treatment for obesity; the CEO for SATOR Therapeutics, an early stage company with an oncolytic virus platform; and the CTO for Diasome Pharmaceuticals, a clinical stage company with a liver targeting technology for the treatment of diabetes.

Prior to BioEnterprise, he founded Oligasis (now known as Kodiak), a biopharmaceutical company developing treatments for retinal diseases, and played key development roles in multiple successful, marketed product platforms, including J&J Ortho’s Vitros central laboratory diagnostic system, GE Healthcare’s Biacore biosensor, CooperVision’s Proclear range of contact lenses, Medtronic’s Endeavor drug-eluting coronary stent, and several PEGylated biopharmaceutical products. Stephen is an inventor on over 25 patents, and earned his B.Sc. and Ph.D. degrees in biochemistry from the University of London.